Showing 6861-6870 of 7584 results for "".
- Researchers Close in on Cause of Inflammation in Rosaceahttps://practicaldermatology.com/news/researchers-close-in-on-cause-of-inflammation-in-rosacea/2458091/Once developed, therapies that block TRPV4 may help treat or prevent inflammation in patients with rosacea, according to new research funded by the National Rosacea Society (NRS). In earlier research, the team l
- Bonti's Novel Gateway Neuromodulator Performs Well in Phase 2A Studyhttps://practicaldermatology.com/news/bontis-novel-serotype-e-botulinum-toxin-performs-well-in-phase-2a-study/2458094/Bonti’s lead product candidate, EB- 001, passed muster in a Phase 2A study for the treatment of glabellar lines. EB-001 is a novel serotype E botulinum neurotoxin with a unique efficacy profile, characterized by fast onset of action (about 24 hours
- Research on Nitric Oxide-Releasing Nanoparticles Reveals Promising Skin Infection Treatmenthttps://practicaldermatology.com/news/research-on-nitric-oxide-releasing-nanoparticles-reveals-promising-skin-infection-treatment/2458095/George Washington University (GW) researchers have found that topically applied nitric oxide-releasing nanoparticles (NO-np) are a viable treatment for deep fungal infections of the skin caused by dermatophyt
- Environmental Groups Sue FDA to Take Formaldehyde Out of Salonshttps://practicaldermatology.com/news/environmental-groups-sue-fda-to-take-formaldehyde-out-of-salons/2458096/The Environmental Working Group (EWG) and Women’s Voices for the Earth (WVE) are suing the Food and Drug Administration (FDA) because of the group’s failure to act on dangerous hair straighteners that contain unsafe levels of formaldehyde and pose a significant health hazard to consum
- Valeant Launches Siliq Injection for Psoriasishttps://practicaldermatology.com/news/valeant-launches-siliq-injection-for-psoriasis/2458107/Valeant Pharmaceuticals International, Inc. launched Siliq (brodalumab) Injection during the Summer American Academy of Dermatology (AAD) meeting taking place in New York from July 27-30, 2017. Siliq, a
- Simulation Techniques Help Medical Students Empathize with Melanoma Patientshttps://practicaldermatology.com/news/simulation-techniques-help-medical-students-empathize-with-melanoma-patients/2458110/Simulation techniques can allow doctors to experience what it feels like to be a melanoma patient. The study, which is led by Queen’s University in Belfast collaboration with researchers from the University of Huddersfield and University College Dublin, appears in the
- Study IDs Risk Factors for Melanoma in Kidney Transplant Recipientshttps://practicaldermatology.com/news/study-ids-risk-factors-for-melanoma-in-kidney-transplant-recipients/2458108/Kidney transplant patients appear to be at a greater risk of developing melanoma than the general population and risk factors include being older, male and white, findings that corroborate results demonstrated in other studies, according to a new article published by
- Early Use of CO2 Lasers on Surgical Scars Bests Silicone Gel Treatmenthttps://practicaldermatology.com/news/early-use-of-co2-lasers-on-surgical-scars-bests-silicone-gel-treatment/2458112/Early treatment of surgical scars with a super-pulsed fractional C02 laser shows promise, new research suggests. The study, which appears in Lasers in Surgery and Medicine (LSM), found that laser treatment of
- DermTech Secures Billing Codes for its Proprietary Melanoma Testhttps://practicaldermatology.com/news/dermtech-secures-billing-codes-for-its-proprietary-melanoma-test/2458115/The American Medical Association (AMA) has granted DermTech, Inc. Category 1, Tier 2 Molecular Pathology procedure codes related to its proprietary test for the detection of melanoma related gene expression. The company has secured this Common Procedural Terminology (CPT) coding for LINC and PRAM
- Valeant to Sell Obagi Medical Products Business for $190 Mhttps://practicaldermatology.com/news/valeant-to-sell-obagi-medical-products-business-for-190-m/2458117/Valeant Pharmaceuticals International, Inc. has entered into an agreement to sell its Obagi Medical Products business for $190 million in cash to Haitong International Zhonghua Finance Acquisition Fund I, L.P. Limited partners of the Fund include industry veterans in other geographic ma